Circulating microRNAs in seminal plasma as predictors of sperm retrieval in microdissection testicular sperm extraction

Ying Zhang^{1,2#}^, Yuan Tang^{1#}, Jing Huang^{3#}^, Huang Liu^{2,4}^, Xiaohua Liu^{2,4}^, Yu Zhou^{2,4}^, Chunjie Ma^{2,4}^, Qiling Wang^{2,4}^, Jigao Yang³^, Fei Sun¹, Xinzong Zhang^{2,4}^

¹Institute of Reproductive Medicine, Medical School, Nantong University, Nantong, China; ²Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital), Guangzhou, China; ³NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing, China; ⁴NHC Key Laboratory of Male Reproduction and Genetics, Guangzhou, China

Contributions: (I) Conception and design: Y Zhang, X Zhang; (II) Administrative support: F Sun, X Zhang, Q Wang; (III) Provision of study materials or patients: J Huang, H Liu, Y Zhou, C Ma; (IV) Collection and assembly of data: Y Tang, J Huang, X Liu, J Yang; (V) Data analysis and interpretation: Y Zhang, Y Tang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work.

Correspondence to: Fei Sun. Nantong University Professor, Institute of Reproductive Medicine, Medical School, Nantong University, 9 Seyuan Road, Nantong 226019, China. Email: sunfei@ntu.edu.cn; Ying Zhang, MD, PhD. Nantong University Associate Professor, Institute of Reproductive Medicine, Medical School, Nantong University, 9 Seyuan Road, Nantong 226019, China. Email: clairezhang@ntu.edu.cn; Xinzong Zhang. NHC Key Laboratory of Male Reproduction and Genetics, Guangzhou Professor, 17 Meidong Road, Guangzhou 510000, China. Email: 13857170787@139.com.

Background: Because of focal spermatogenesis in some nonobstructive azoospermia (NOA) patients, testicular spermatozoa can be retrieved by microdissection testicular sperm extraction (micro-TESE) for intracytoplasmic sperm injection (ICSI) to achieve successful fertilization. Currently, testicular biopsy is widely performed for the prognosis of micro-TESE; however, it might miss foci with active spermatogenesis because of the 'blind manner' of puncture, highlighting the needs for biomarkers that could indicate actual spermatogenesis conditions in the testis. Thus, we screened microRNAs in the seminal plasma for potential biomarkers to provide a non-invasive and reliable preoperative assessment for micro-TESE.

Methods: We screened the seminal plasma microRNAs from NOA patients with and without sperm retrieval (n=6 in each group) together with fertile men (n=6) by RNA sequencing, and the selected microRNAs were validated by quantitative polymerase chain reaction (qPCR). Next, a predictive model was established by performing ordered logistic regression using the qPCR data of 56 specimens, and the predictive accuracy of this model was evaluated using 40 more specimens in a blind manner.

Results: Four microRNAs (hsa-miR-34b-3p, hsa-miR-34c-3p, hsa-miR-3065-3p, and hsa-miR-4446-3p) were identified as biomarkers, and the predictive model Logit = 2.0881+ 0.13448 mir-34b-3p + 0.58679 mir-34c-3p + 0.15636 mir-3065-3p + 0.09523 mir-4446-3p was established by machine learning. The model provided a high predictive accuracy (AUC =0.927).

Conclusions: We developed a predictive model with high accuracy for micro-TESE, with which NOA patients might obtain accurate assessment of spermatogenesis conditions in testes before surgery.

Keywords: Nonobstructive azoospermia; microdissection testicular sperm extraction (micro-TESE); spermatogenesis; microRNA; biomarker

Submitted Sep 25, 2021. Accepted for publication Jan 10, 2022. doi: 10.21037/atm-21-5100 View this article at: https://dx.doi.org/10.21037/atm-21-5100

^ ORCID: Ying Zhang 0000-0002-7889-7124; Jing Huang, 0000-0002-1367-6582; Huang Liu, 0000-0001-8889-9054; Xiaohua Liu, 0000-0003-0905-1456; Yu Zhou, 0000-0003-0117-745X; Chunjie Ma, 0000-0002-6909-2076; Qiling Wang, 0000-0003-1635-0198; Jigao Yang, 0000-0002-0427-0337; Xinzong Zhang, 0000-0002-7014-7900.

Page 2 of 12

Introduction

Approximately 10-15% of couples experience infertility, and approximately 50% of these cases are caused by male infertility, of which approximately 10% represent the most severe manifestation, named nonobstructive azoospermia (NOA) (1). NOA is characterized by the complete absence of sperm in semen due to impaired spermatogenesis in the testes. However, because of focal spermatogenesis, testicular spermatozoa can be retrieved by microdissection testicular sperm extraction (micro-TESE) for intracytoplasmic sperm injection (ICSI) to achieve successful fertilization in some NOA patients (2-5). The major challenge with micro-TESE is to find predictors of active spermatogenesis foci indicating the likelihood of recovering sperm (6). It is essential to evaluate the sperm retrieval likelihood to determine whether the patient is currently suitable for micro-TESE. In particular, for patients receiving certain medications to enhance spermatogenesis recovery before the operation, the optimal operation time must be estimated according to the prognosis (7). Currently, testicular biopsy is widely performed for the prognosis of micro-TESE; however, it might miss foci with active spermatogenesis because of the "blind manner" of puncture (8-11). Additionally, as an invasive method, testicular biopsy may lead to severe complications (12). Therefore, a more reliable and safer prognostic method is needed.

Seminal plasma is the liquid component of semen, which arises from secretions from the seminal vesicles (~65%), prostate (~25%), testes and epididymides (~10%) and periurethral glands (~1%) (13). Secretions from the testes and epididymides provide molecules related to spermatogenesis and spermatozoa maturation, which could be potential biomarkers prompting spermatogenesis conditions (13-15). Several studies have reported proteins, circulating cells and cell-free DNA/RNA as potential biomarkers of nonobstructive azoospermia subtypes (16-18). Among these factors, circulating microRNAs could be ideal candidates because of their smaller size and encapsulation within proteins as they are less susceptible to degradation than other RNA species. MicroRNAs are a family of noncoding RNAs of approximately 19-23 nucleotides (nt) long that function as regulators of messenger RNA (mRNA) stability and translation (19). Many studies have indicated that microRNAs are involved in spermatogenesis and that aberrant expression of some microRNAs is related to male infertility (20-25). MicroRNAs have been reported as reliable biomarkers in various biopsies due to their stable characteristics (26,27). As one of the most important

Zhang et al. MicroRNAs as biomarkers of spermatogenesis

regulators of spermatogenesis, they have also been detected in human spermatozoa and seminal plasma (28). Several studies have investigated microRNAs in seminal plasma using either microarray or exosome microRNA profiling for indicators of spermatogenesis (29-31). However, neither microarray nor exosome microRNA profiling represents the total microRNAs that exist in the seminal plasma. Furthermore, those studies were limited by one or more of the following reasons: a lack of model establishment, a limited number of patients, and a lack of clinical validation.

In the present study, we screened whole microRNAs in seminal plasma from different groups of patients by improved absolute quantitative high-throughput small RNA sequencing (sRNA-seq) for more reliable biomarkers, and 4 microRNAs were identified as potential predictors through multiplex reverse transcription-quantitative polymerase chain reaction (RT-qPCR). A microRNA predictive model was established by ordered logistic regression through machine learning with qPCR data. The model was used to assess testicular spermatogenesis ratings to accurately estimate the likelihood of sperm retrieval in micro-TESE. Independent clinical validation of the model was performed to evaluate the predictive accuracy of the model (32). We present the following article in accordance with the STARD reporting checklist (available at https://atm.amegroups. com/article/view/10.21037/atm-21-5100/rc).

Methods

Patients and study design

All seminal plasma samples in this study were collected from Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Research Ethics Committee of Guangdong Provincial Reproductive Science Institute (Guangdong Provincial Fertility Hospital) (No. 2019025), and individual consent for this retrospective analysis was waived.

The samples were divided into 3 sets for different purposes in the study, including the screening set, training set and test set (*Figure 1*). Each set contained 3 groups that were divided according to the following testicular spermatogenesis conditions: (I) the "good" (G) group comprised fertile semen from the sperm bank, representing normal spermatogenesis; (II) the "fair" (F) group comprised NOA patients with 100% sperm retrieval in micro-TESE, representing hypospermatogenesis (existence of focal

Annals of Translational Medicine, Vol 10, No 7 April 2022



Figure 1 Study design. Flow diagram of the study. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; UMI, unique molecular index; sRNA-seq, small RNA sequencing.

spermatogenesis); and (III) the "poor" (P) group comprised NOA patients with no sperm retrieval in micro-TESE, representing no active spermatogenesis. The screening set was used to identify significantly differentially expressed microRNAs as potential biomarkers for spermatogenesis. The training set was used for machine learning to construct ordered logistic regression modeling and establish a predictive model. The test set evaluated the model in which the RT-qPCR data of this set were applied to the model for prognosis, and the output result was compared with the clinical micro-TESE record to test the accuracy.

Seminal plasma small RNA purification

Polysaccharides make seminal plasma highly viscous, and routine small RNA (sRNA) purification methods for liquid samples, such as the solid-phase reversible immobilization (SPRI) bead-based method and TRIzol-LS method, produce significantly low amounts of sRNAs with large amounts of polysaccharide retention. To improve the quantity and quality of seminal plasma sRNAs, we combined the TRIzol-LS precipitation and column purification methods (Appendix 1). The concentration and purity of the enriched sRNAs were checked with NanoDrop One (Thermo Fisher Scientific, Waltham, MA, USA). The size distribution of the sRNAs was detected on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) (Table S1).

Absolute quantitative high-throughput sRNA sequencing (HTS) using a unique molecular index (UMI) and bioinformatic analysis

MicroRNA library construction for HTS includes a PCR amplification step, which can introduce a vast amount of bias because of the complicated structures of microRNAs. For seminal plasma microRNA, which has a low input of the starting materials, more cycles of PCR amplification are needed to obtain a sufficient amount for sequencing. Increased PCR amplification cycles produce more bias than microRNAs from other samples. To reduce PCR-derived artifacts, we adopted absolute quantitative microRNA sequencing with UMIs (Figure S1A) (33). This method could distinguish original copies of microRNAs from their

Table 1 Baseline characteristic	s of enrolled NOA patients
---------------------------------	----------------------------

Characteristics (mean \pm SD)	Fair group (n=48)	Poor group (n=68)
Male age (years)	30±4	31±5
Female partner age (years)	28±5	28±4
Infertile duration (years)	4±2	4±2
Testicular volume (mL)	14±3*	12±5*
Serum FSH (IU/L)	15.33±8.01*	15.75±8.12*
Serum LH (IU/L)	7.02±5.05*	7.87±5.73*

*, no significant difference, Student's *t*-test. NOA, nonobstructive azoospermia; FSH, follicle-stimulating hormone; LH, luteinizing hormone.

amplification products by barcoding a random hexamer sequence as the UMI to each microRNA before PCR. After amplification, although multiple counts of each UMI could be observed, we precisely quantified the original copy number of each microRNA by simply counting each UMI. This UMI-based microRNA sequencing provided us with more reliable differentially expressed genes (DEGs) between groups and increased the efficiency of the validation progress by reducing the number of false DEGs. For normalization, we synthesized cel-miR-39 (TaKaRa Bio., Dalian, China) as a spike-in reference microRNA. Exactly 250 fmol of cel-miR-39 was added to each seminal plasma sample before sRNA purification. Approximately 100 ng of sRNAs per sample was used in library construction for HTS. During library construction, UMI-labeled primers were added (Figure S1A). All the samples were sequenced on a BGISEQ-500 system (Beijing Genomics Institution, Shenzhen, China), and bioinformatic analysis was performed following the standard pipeline (Figure S1B).

Multiplex RT-qPCR for microRNAs

Five microliters of sRNA were used as the template for a 20-µL reaction. RT-qPCR was designed based on the stemloop method (Figure S2) (34). All the primers and probes used in this study are provided in Table S2. A multiplex RT reaction with 13 microRNA-specific stem-loop primers (SLPs) was performed, and an optimized pulsed RT reaction condition was applied to reduce nonspecific reactions and increase the RT efficiency (Appendix 1) (35). To increase the sensitivity of the qPCR, preamplification (pre-PCR) of the complementary DNA (cDNA) templates

Zhang et al. MicroRNAs as biomarkers of spermatogenesis

was necessary. The total RT product was used as a template, together with a specific forward primer (FP) cocktail (mixture of 13 microRNA-specific primers) and universal reverse primer (URP) (Appendix 1). To remove additional primers and deoxy-ribonucleoside triphosphate (dNTPs) in the pre-PCR product, which might affect qPCR, we performed cleanup treatment with ExoSAP-IT reagent (Thermo Fisher Scientific, Waltham, MA, USA; #75001) (Appendix 1). The products were purified using a MinElute PCR Purification Kit (Qiagen, Hilden, Germany; #28004) to obtain template pools for qPCR. Fluorescent dye-based qPCR was performed for candidate biomarker selection, and hydrolysis probe-based qPCR was performed for the construction of the predictive model (Appendix 1). To test the sensitivity of the stem-loop RT-qPCR-based microRNA expression profiling method in the multiplex format, we constructed the standard curve and R² of each microRNA qPCR (Figure S3).

Statistical analysis

The input data for the analysis were the Δ Cq values (the Cq values of specific microRNAs minus the Cq values of the reference microRNA cel-miR-39). The fold change (FC) of the expression level was calculated as $2^{-\Delta Cq}$ or $2^{-\Delta Cq}$. All statistical analyses were performed using R script. We established a predictive microRNA model based on training data using the function Polr (proportional odds logistic regression) of the MASS package in R-studio. A model fitting test was performed to evaluate the model. Receiver operating characteristic (ROC) curves were constructed to test the predictive accuracy of the model.

Results

Patient characteristics

The baseline characteristics of the NOA patients in this study are presented in *Table 1*. Testicular sperm was successfully retrieved in the fair group (age 30 ± 4), and no sperm was retrieved in the poor group (age 31 ± 5). There was no significant difference in the distribution of age, female partner age or testicular volume between the fair group and poor group. The mean follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in the fair group (FSH 15.33 IU/L, 95% CI: 12.22–18.43; LH 7.02 IU/L, 95% CI: 5.06–8.97) were not significantly different (P=0.84; P=0.55) from those of the poor group

Annals of Translational Medicine, Vol 10, No 7 April 2022



Figure 2 Selection of differentially expressed microRNAs from sRNA-seq. (A) A total of 489 microRNAs were identified as differentially expressed microRNAs among 18 samples. (B) Intergroup analysis identified 80 differentially expressed microRNAs among the good, fair and poor groups; sRNA-seq, small RNA sequencing.

(FSH 15.75 IU/L, 95% CI: 12.60–18.90; LH 7.87 IU/L, 95% CI: 5.64–10.09).

MicroRNA screening for candidate biomarkers

Our RNA-seq detected 786 known microRNAs from 18 samples, among which 158 were identified as differentially expressed microRNAs among groups based on the bioinformatic analysis with DEGseq, and 80 were defined as significantly differentially expressed microRNAs based on the expression FC (log2FC >2; P<0.01) (*Figure 2*). We further narrowed the range of candidates to 12 microRNAs

(hsa-miR-34b-3p, hsa-miR-676-3p, hsa-miR-376a-3p, hsa-miR-449b-3p, hsa-miR-202-5p, hsa-miR-942-5p, hsa-miR-518e-3p, hsa-miR-891b, hsa-miR-4446-3p, hsa-miR-3065-3p, hsa-miR-30b-3p, and hsa-miR-34c-3p) based on their expression levels and patterns. We first eliminated 41 low-abundance microRNAs (expression level <20) and then divided the other 39 microRNAs into 4 groups based on their expression patterns in the 3 groups (*Figure 3*). We selected 2 groups of microRNAs whose expression patterns were consistent with the trend of spermatogenic situations from good to poor (*Figure 3C, 3D*). The selected 2 groups contained 12 microRNAs in total, among

Page 6 of 12

Zhang et al. MicroRNAs as biomarkers of spermatogenesis



Figure 3 Expression patterns of the selected microRNAs in the three groups. Four patterns were identified based on the expression level changes from the "good" group to the "poor" group.

which 9 microRNAs showed a positive correlation with active spermatogenesis, and 3 showed an opposite trend (*Figure 3C*,3*D*). In summary, 12 significantly differentially expressed microRNAs were identified as candidates for further validation via RT-qPCR.

Differential expression profile of selected microRNAs

The 12 candidate microRNAs were tested by RT-qPCR with the 3 groups of sequencing samples to validate the FC of the expression level. We first tested the sensitivity of the stem-loop RT-qPCR-based microRNA expression profiling method in multiplex format. The standard curve and R² of each microRNA qPCR were constructed. Among the 12 microRNAs, hsa-miR-202-5p, hsa-miR-518e-3p and

hsa-miR-891b had R² values of 0.9748, 0.9535 and 0.9312, respectively, and the other 9 microRNAs all had R² values >0.99, indicating a sensitive and optimal amplification efficiency (Figure S3). Among these 12 microRNAs, only 4 (hsa-miR-34b-3p, hsa-miR-34c-3p, hsa-miR-3065-3p, and hsa-miR-4446-3p) displayed significantly differential expression patterns (*Figure 4*). The expression levels of hsa-miR-34b-3p and hsa-miR-34c-3p were significantly decreased from the "G" to the "P", indicating that they are potential biomarkers for active spermatogenesis. The FC of the expression level of hsa-miR-34b-3p for "F"/"G" was 0.12 (P<0.001) and that for "P"/"G" was 0.03 (P<0.001). The FC of the expression level of hsa-miR-34c-3p for "F"/"G" was 0.62 (P<0.05) and that for "P"/"G" was 0.09 (P<0.001). The expression levels of hsa-miR-3065-3p and hsa-miR-4446-3p



Figure 4 Selection of potential predictors by RT-qPCR. Expression profile of the 12 selected microRNAs in the different groups. RT-qPCR data of the 12 selected microRNAs showed the relative expression levels in the "good", "fair" and "poor" groups. Among these 12 microRNAs, miR-34b-3p and miR-34c-3p were significantly downregulated from the "good" group to the "poor" group, and miR-4446-3p and miR-3065-3p were significantly upregulated from the "good" group. (***P<0.001, **P<0.01, *P<0.05). RT-qPCR, reverse transcription-quantitative polymerase chain reaction.

were significantly increased from the "G" group to the "P" group, indicating the severity of impaired spermatogenesis. The FC of the expression level of hsa-miR-3065-3p for "F"/"G" was 2.94 (P<0.01) and that for "P"/"G" was 3.44 (P<0.05). The FC of the expression level of hsa-miR-4446-3p for "F"/"G" was 2.66 (P<0.001) and that for "P"/"G" was 3.36 (P<0.01). Therefore, hsa-miR-34b-3p, hsa-miR-34c-3p, hsa-miR-3065-3p and hsa-miR-4446-3p were identified as candidate biomarkers for model establishment with the training set.

Establishment of the microRNA predictive model

Higher expression levels of hsa-miR-34b-3p and hsa-miR-34c-3p prompted more normal spermatogenesis and a higher possibility of retrieving sperm from micro-TESE. In contrast, higher expression levels of hsa-miR-3065-3p and hsa-miR-4446-3p implied more seriously impaired spermatogenesis and a lower likelihood of retrieving viable sperm. Thus, to examine how the expression levels of these 4 microRNAs predict the sperm retrieval outcome of micro-TESE, we performed an ordered logistic regression analysis. The input data for the ordered logistic regression analysis were the ΔCq values of the 4 microRNAs from the training set (G group =6; F group =20; P group =30). We established the formula by estimating regression coefficients and the intercept in R using the Polr function in the MASS package (Table 2). The predicted probabilities of being estimated as "good", "fair" and "poor" were denoted as "Pg", "Pf" and "Pp", respectively. According to the ordered logistic regression, we established the following formulas: Logit (Pg) = 2.9414 +0.08932 hsa.miR.34b.3p + 0.59866 hsa.miR.34c.3p + 0.23658 hsa.miR.3065.3p + 0.19814 hsa.miR.4446.3p; Logit (Pg + Pf) = 3.9007 + 0.08932 hsa.miR.34b.3p + 0.59866 hsa.miR.34c.3p + 0.23658 hsa.miR.3065.3p + 0.19814 hsa.miR.4446.3p. Pp = 1 - (Pg + Pf).

Accuracy test of the predictive model

To evaluate the performance of the predictive model, we

Page 8 of 12

Table 2 The predictive formula model for micro-TESE

Variable	Value	Std.Error	t value
Coefficients			
hsa.miR.34b.3p	0.13448	0.3400	0.3956
hsa.miR.34c.3p	0.58679	0.3704	1.5843
hsa.miR.3065.3p	0.15636	0.4112	0.3802
hsa.miR.4446.3p	0.09523	0.3542	0.2688
Intercepts			
$G F^{\dagger}$	2.0881	2.7436	0.7611
F P [‡]	3.0533	2.7656	1.1040

 $\begin{array}{l} {\sf polr}({\sf formula} = {\sf as.ordered}({\sf result}) - {\sf hsa.miR.34b.3p} + {\sf hsa.miR.34c.3p} + {\sf hsa.miR.3065.3p} + {\sf hsa.miR.4446.3p}). \ ^{+}, {\sf Logit}({\sf Pg}) \\ {\sf = 2.0881} + 0.13448 \ {\sf hsa.miR.34b.3p} + 0.58679 \ {\sf hsa.miR.34c.3p} \\ {\sf + 0.15636} \ {\sf hsa.miR.3065.3p} + 0.09523 \ {\sf hsa.miR.4446.3p}. \ ^{+}, \\ {\sf Logit}({\sf Pg} + {\sf Pf}) = 3.0533 + 0.13448 \ {\sf hsa.miR.34b.3p} + 0.58679 \\ {\sf hsa.miR.34c.3p} + 0.15636 \ {\sf hsa.miR.3065.3p} + 0.09523 \ {\sf hsa.} \\ {\sf miR.34c.3p} + 0.15636 \ {\sf hsa.miR.3065.3p} + 0.09523 \ {\sf hsa.} \\ {\sf miR.4446.3p}. \ {\sf Pp} = 1 - {\sf Pg-Pf}. \ {\sf micro-TESE}, \ {\sf microdissection} \\ {\sf testicular sperm extraction}. \end{array}$

Table 3 Predictive model output

Predictive result	Good	Fair	Poor	Total
Good	6	2	0	8
Fair	0	8	1	9
Poor	0	2	21	23
Total	6	12	22	-
Accuracy	100%	66.67%	95.45%	-

Table 4 Predictive model evaluation

Dradiativa regult	Clinical result				
Fredictive result	Positive (+)	Negative (-)	Total		
Positive (+)	16	2	18		
Negative (-)	1	21	22		
Total	17	23	-		

Predictive result: FPR 8.70%; FNR 5.88%; TPR 88.89%; TNR 95.45%. Clinical result: sensitivity 94.12%; specificity 91.30%. FPR, false positive rate; FNR, false negative rate; TPR, true positive rate; TNR, true negative rate.

tested 40 samples with the model in a "blind" manner, meaning no clinical information was provided beforehand. We compared the results acquired from the predictive

Zhang et al. MicroRNAs as biomarkers of spermatogenesis

model to the clinical micro-TESE results. The clinical information revealed the following: 6 samples were from fertile men, denoted as "good"; 12 samples were from NOA patients with positive sperm retrieval, denoted as "fair"; and 22 samples were from NOA patients with negative sperm retrieval, denoted as "poor". The prediction for the 40 samples from our model showed that all 6 fertile men were identified as in the "good" group, and 21 out of 22 patients with negative sperm retrieval were identified as in the "poor" group, indicating 100% and 95.45% accuracy rates in predicting patients who might show 100% and 0% sperm retrieval rates in micro-TESE, respectively (Table 3). For the 12 patients with positive sperm retrieval in micro-TESE, 8 were identified as in the "fair" group, 2 were identified as in the "good" group and 2 were identified as in the "poor" group. Because we claimed that both the "good" and "fair" groups represented the existence of active spermatogenesis in the testes, both samples appeared in the "good" and "fair" groups, implying a positive sperm retrieval likelihood in micro-TESE. Therefore, the accuracy rate for predicting sperm retrieval was 83.33%. We also calculated the sensitivity and specificity of the predictive model, which were 94.12% and 91.30%, respectively (Table 4). ROC curves were constructed based on the predictive performance of identifying positive sperm retrieval versus negative sperm retrieval (AUC =0.927), as well as for identifying "good" versus "poor" (AUC =0.955), "fair" versus "poor" (AUC =0.913) and "good" versus "fair" (AUC =0.707) (Figure 5).

Discussion

As an effective method to retrieve testicular sperm from NOA patients, micro-TESE appears to be safe and has a higher yield of sperm than other methods. However, positive sperm retrieval was not possible from all patients. Thus, providing doctors and patients with a method for assessing the likelihood of retrieving sperm is essential, particularly when the patient requests another operation attempt following a failed sperm retrieval. Testicular biopsy, testicular ultrasound and hormone levels are assessment methods before micro-TESE; however, because of the heterogeneity of testicular tissue, these methods lack particular effectiveness (36). Several studies have been performed to identify molecular biomarkers of active spermatogenesis from seminal plasma, such as PIWIinteracting RNAs (piRNAs), mRNAs and microRNAs; however, these studies either lacked model construction or



Figure 5 ROC curve analysis for the performance of the predictive model. (A) ROC curve for the predictive model discriminating the "success" group from the "fair" group, AUC 0.927; (B) ROC curve for the predictive model discriminating the "good" group from the "poor" group, AUC 0.955; (C) ROC curve for the predictive model discriminating the "fair" group from the "poor" group, AUC 0.913; (D) ROC curve for the predictive model discriminating the "fair" group, AUC 0.913; (D) ROC curve for the predictive model discriminating the "fair" group, AUC 0.707. AUC, area under the curve. 0.5< AUC <1 indicates for good predictive value. ROC, receiver operating characteristic; AUC, area under the curve.

only established binary classification models (37).

In this study, we performed an ordered logistic regression with the 4 microRNAs identified from small RNA-seq and RT-qPCR for rating testicular spermatogenesis. With the predictive model we developed, patients could be sorted into 3 groups (good, fair and poor) based on their spermatogenesis conditions, allowing them to receive the appropriate treatment for a higher sperm retrieval rate. The model identified the "good" and "poor" samples with higher accuracy, and the more extreme the situation was, the more accurate the result was. However, for moderate-quality samples, the accuracy of the model must be improved. To improve the accuracy of micro-TESE outcome prediction, other factors should be considered together with the microRNA model to form a "predictive system". For example, seminal plasma piRNAs, mRNA elements, long noncoding RNAs (lncRNAs), circulating DNAs, exfoliative cells, together with the histological diagnosis could be considered together for outcome prediction. We also summarized the histological results of the patients with different micro-TESE outcomes in this study (Table S3, Figure S4). Multiple panels should be established and combined by machine learning to make more accurate predictions. For the outcomes of assisted reproduction after micro-TESE, if testicular spermatozoa are retrieved by micro-TESE, NOA patients could achieve fatherhood via intracytoplasmic sperm injection (ICSI). The time of sperm retrieval and the time of egg retrieval from the partner might not be the same. There are 3 ways to select the timing of ICSI: egg and sperm retrieval in the same cycle, frozen egg recovery combined with sperm retrieval, and frozen sperm recovery combined with egg retrieval. Each method has certain limitations, such as the recovery rate of frozen eggs and sperm. In this study, according to the clinical records, among the 53 NOA patients who achieved successful sperm retrieval, 24 couples underwent ICSI, and

Page 10 of 12

17 couples achieved a successful pregnancy. The other 29 patients froze their sperm for later use.

Conclusions

In this study, we established a predictive model to detect the possibility of sperm retrieval outcomes in micro-TESE. Our study has demonstrated that this model could provide considerable clinical value in identifying samples with a high likelihood of sperm retrieval and is valuable to direct the selection of the optimal time for operation planning.

Acknowledgments

Funding: This work was supported by the following grants: the National Natural Science Foundation of China (Grant No. 81801523 to YZ), the Guangzhou Municipal Science and Technology Bureau of China (Grant No. 201904010017 to YZ and No. 201707010394 to XZ), the Natural Science Foundation of Guangdong Province (Grant No. 2021A1515011544 to XZ), and the Chongqing Research Institute Performance Incentive and Guidance Project (No. cstc2018jxj l120004 to JH).

Footnote

Reporting Checklist: The authors have completed the STARD reporting checklist. Available at https://atm.amegroups.com/article/view/10.21037/atm-21-5100/rc

Data Sharing Statement: Available at https://atm.amegroups. com/article/view/10.21037/atm-21-5100/dss

Peer Review File: Available at https://atm.amegroups.com/ article/view/10.21037/atm-21-5100/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm. amegroups.com/article/view/10.21037/atm-21-5100/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Research Ethics Committee of Guangdong Provincial Reproductive

Zhang et al. MicroRNAs as biomarkers of spermatogenesis

Science Institute (Guangdong Provincial Fertility Hospital) (No. 2019025), and individual consent for this retrospective analysis was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- 1. Jarow JP, Espeland MA, Lipshultz LI. Evaluation of the azoospermic patient. J Urol 1989;142:62-5.
- 2. Friedler S, Raziel A, Strassburger D, et al. Testicular sperm retrieval by percutaneous fine needle sperm aspiration compared with testicular sperm extraction by open biopsy in men with non-obstructive azoospermia. Hum Reprod 1997;12:1488-93.
- Schlegel PN. Testicular sperm extraction: microdissection improves sperm yield with minimal tissue excision. Hum Reprod 1999;14:131-5.
- Donoso P, Tournaye H, Devroey P. Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review. Hum Reprod Update 2007;13:539-49.
- Ostad M, Liotta D, Ye Z, et al. Testicular sperm extraction for nonobstructive azoospermia: results of a multibiopsy approach with optimized tissue dispersion. Urology 1998;52:692-6.
- Westlander G. Utility of micro-TESE in the most severe cases of non-obstructive azoospermia. Ups J Med Sci 2020;125:99-103.
- Deruyver Y, Vanderschueren D, Van der Aa F. Outcome of microdissection TESE compared with conventional TESE in non-obstructive azoospermia: a systematic review. Andrology 2014;2:20-4.
- Takada S, Tsujimura A, Ueda T, et al. Androgen decline in patients with nonobstructive azoospemia after microdissection testicular sperm extraction. Urology 2008;72:114-8.
- Tsujimura A, Matsumiya K, Miyagawa Y, et al. Conventional multiple or microdissection testicular sperm extraction: a comparative study. Hum Reprod

2002;17:2924-9.

- Ramasamy R, Yagan N, Schlegel PN. Structural and functional changes to the testis after conventional versus microdissection testicular sperm extraction. Urology 2005;65:1190-4.
- Colpi GM, Colpi EM, Piediferro G, et al. Microsurgical TESE versus conventional TESE for ICSI in nonobstructive azoospermia: a randomized controlled study. Reprod Biomed Online 2009;18:315-9.
- Ghalayini IF, Al-Ghazo MA, Hani OB, et al. Clinical comparison of conventional testicular sperm extraction and microdissection techniques for non-obstructive azoospermia. J Clin Med Res 2011;3:124-31.
- Drabovich AP, Saraon P, Jarvi K, et al. Seminal plasma as a diagnostic fluid for male reproductive system disorders. Nat Rev Urol 2014;11:278-88.
- Ramasamy R, Lin K, Gosden LV, et al. High serum FSH levels in men with nonobstructive azoospermia does not affect success of microdissection testicular sperm extraction. Fertil Steril 2009;92:590-3.
- Osaka A, Iwahata T, Kobori Y, et al. Testicular volume in non-obstructive azoospermia with a history of bilateral cryptorchidism may predict successful sperm retrieval by testicular sperm extraction. Reprod Med Biol 2020;19:372-7.
- Drabovich AP, Dimitromanolakis A, Saraon P, et al. Differential diagnosis of azoospermia with proteomic biomarkers ECM1 and TEX101 quantified in seminal plasma. Sci Transl Med 2013;5:212ra160.
- Li HG, Huang SY, Zhou H, et al. Quick recovery and characterization of cell-free DNA in seminal plasma of normozoospermia and azoospermia: implications for noninvasive genetic utilities. Asian J Androl 2009;11:703-9.
- Wu W, Hu Z, Qin Y, et al. Seminal plasma microRNAs: potential biomarkers for spermatogenesis status. Mol Hum Reprod 2012;18:489-97.
- Bartel DP. MicroRNA Target Recognition and Regulatory Functions. Cell 2009;136:215-33.
- Ro S, Park C, Sanders KM, et al. Cloning and expression profiling of testis-expressed microRNAs. Dev Biol 2007;311:592-602.
- Yuan S, Schuster A, Tang C, et al. Sperm-borne miRNAs and endo-siRNAs are important for fertilization and preimplantation embryonic development. Development 2016;143:635-47.
- Wu J, Bao J, Kim M, et al. Two miRNA clusters, miR-34b/c and miR-449, are essential for normal brain development, motile ciliogenesis, and spermatogenesis.

Proc Natl Acad Sci U S A 2014;111:E2851-7.

- 23. Zhang Y, Tang C, Yu T, et al. MicroRNAs control mRNA fate by compartmentalization based on 3' UTR length in male germ cells. Genome Biol 2017;18:105.
- Bao J, Li D, Wang L, et al. MicroRNA-449 and microRNA-34b/c function redundantly in murine testes by targeting E2F transcription factor-retinoblastoma protein (E2F-pRb) pathway. J Biol Chem 2012;287:21686-98.
- Wu Q, Song R, Ortogero N, et al. The RNase III enzyme DROSHA is essential for microRNA production and spermatogenesis. J Biol Chem 2012;287:25173-90.
- Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
- 27. Huang S, Li H, Ding X, et al. Presence and characterization of cell-free seminal RNA in healthy individuals: implications for noninvasive disease diagnosis and gene expression studies of the male reproductive system. Clin Chem 2009;55:1967-76.
- Daneshmandpour Y, Bahmanpour Z, Hamzeiy H, et al. MicroRNAs association with azoospermia, oligospermia, asthenozoospermia, and teratozoospermia: a systematic review. J Assist Reprod Genet 2020;37:763-75.
- 29. Wang C, Yang C, Chen X, et al. Altered profile of seminal plasma microRNAs in the molecular diagnosis of male infertility. Clin Chem 2011;57:1722-31.
- Zhang W, Zhang Y, Zhao M, et al. MicroRNA expression profiles in the seminal plasma of nonobstructive azoospermia patients with different histopathologic patterns. Fertil Steril 2021;115:1197-211.
- 31. Barceló M, Mata A, Bassas L, et al. Exosomal microRNAs in seminal plasma are markers of the origin of azoospermia and can predict the presence of sperm in testicular tissue. Hum Reprod 2018;33:1087-98.
- Choi SH, Labadorf AT, Myers RH, et al. Evaluation of logistic regression models and effect of covariates for casecontrol study in RNA-Seq analysis. BMC Bioinformatics 2017;18:91.
- Fishman A, Light D, Lamm AT. QsRNA-seq: a method for high-throughput profiling and quantifying small RNAs. Genome Biol 2018;19:113.
- Tang F, Hajkova P, Barton SC, et al. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006;34:e9.
- 35. Moltzahn F, Olshen AB, Baehner L, et al. Microfluidicbased multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011;71:550-60.

Page 12 of 12

36. Gnessi L, Scarselli F, Minasi MG, et al. Testicular histopathology, semen analysis and FSH, predictive value of sperm retrieval: supportive counseling in case of reoperation after testicular sperm extraction (TESE). BMC Urol 2018;18:63.

Cite this article as: Zhang Y, Tang Y, Huang J, Liu H, Liu X, Zhou Y, Ma C, Wang Q, Yang J, Sun F, Zhang X. Circulating microRNAs in seminal plasma as predictors of sperm retrieval in microdissection testicular sperm extraction. Ann Transl Med 2022;10(7):392. doi: 10.21037/atm-21-5100

Zhang et al. MicroRNAs as biomarkers of spermatogenesis

 Cao C, Wen Y, Wang X, et al. Testicular piRNA profile comparison between successful and unsuccessful micro-TESE retrieval in NOA patients. J Assist Reprod Genet 2018;35:801-8.

Supplemental methods

Seminal plasma small RNA purification

Semen samples were obtained by masturbation followed by 30 min of liquefaction at 37 °C. Seminal plasma was obtained by centrifugating semen samples first at 1,500×g for 10 min, and three hundred microliters of seminal plasma were transferred to new tubes, and 1 ml of TRIzol[™] LS Reagent (Thermo Fisher; #10296028) was added, followed by 200 µL of chloroform. Briefly, after mixing thoroughly, the samples were centrifuged at 10,000×g for 15 min to separate phases. Approximately 600 µL of the aqueous phase was carefully transferred into new tubes, and an equal volume of cold isopropanol was added, followed by centrifugation at 15,000×g for 30 min to pellet the total RNA. The RNA pellets were washed twice with 75% ethanol and resolved in 100 µL of hot nuclease-free water. To remove the large amount of polysaccharide coprecipitated with RNA and enrich small RNAs (sRNAs) (<200 nt), we performed sRNA purification using the mirVana[™] miRNA Isolation Kit (Thermo Fisher; #AM1561). Briefly, 500 µL of lysis/binding buffer was added to 100 µL of total RNA together with 50 µL of additive. A 1/3 volume of 100% ethanol was added first to the mixture and passed through the column to remove the large RNAs. The filtrate was saved for sRNA isolation, and a 2/3 volume of 100% alcohol was added to the filtrate and passed through the second column to recover the sRNA. After 3 washes, 30 µL of sRNAs was eluted with nuclease-free water.

Multiplex RT-qPCR for microRNAs

Briefly, 1 µL of 50 nM SLP cocktail (13 SLP mixture)

together with 10 mM dNTPs, 0.1 M DTT, 40 units of RNaseOUT[™] (Thermo Fisher; #10777-019) and 200 units of SuperScriptTM II Reverse Transcriptase (SS II RTase) (Thermo Fisher; #18064014) were used for each RT reaction. All 13 microRNAs were converted into cDNAs in one reaction. The conditions were as follows: 16 °C for 30 min, followed by 60 cycles of 20 °C for 30 s, 42 °C for 30 s, 50 °C for 1 s and termination at 85 °C for 5 min. For the preamplification, the total RT product (20 µL) was used as a template, together with 50 nM of forward primer (FP) cocktail (mixture of 13 microRNA-specific primers), 5 μ M of universal reverse primer (URP) and 25 μ L of 2× Q5[®] High-Fidelity Master Mix (NEB; #M0492L). The conditions for the pre-PCR were 98 °C for 30 s followed by 12 cycles of 98 °C for 10 s, 68 °C for 30 s, 72 °C for 30 s and 72 °C for 5 min. The cleanup treatment with ExoSAP-IT reagent was performed as follows: 10 µL of pre-PCR product together with 4 µL of ExoSAP-IT reagent (Thermo Fisher; #75001) was incubated at 37 °C for 30 min followed by 15 min of inactivation at 80 °C.

One microliter of 1:200 diluted pre-PCR product was used as a qPCR template for a 20-µL reaction, together with 250 nM of FP, 250 nM of URP and 1× TB Green Premix Ex Taq II (TAKARA; #RR820A). The probe qPCR was performed using the same amount of template and primers, together with 0.2 µM of hydrolysis probe and 1× Premix Ex Taq[™] (TAKARA; #RR390L). The conditions were as follows: 95 °C for 30 s, followed by 40 cycles at 95 °C for 10 s and 60 °C for 1 min. All the reactions were run on a LightCycler 480 System (Roche).

Sample No.	Sample name	Con. (ng/µL)	Amount (µg)	RNA integrity number (RIN)	28S/18S	A260/A280	A260/A230
1	P-1471	104	0.88	2.6	0.0	1.92	2.07
2	P-3073	32	0.27	1.1	0.0	1.95	2.2
3	P-3072	23	0.21	2.6	0.0	2.01	2.13
4	P-2972	19	0.15	2.5	0.0	1.95	2.12
5	P-3306	19	0.16	2.5	0.0	1.91	2.08
6	P-3204	16	0.14	2.4	0.0	2.03	2.14
7	F-361	134	1.21	2.6	0.0	1.97	2.02
8	F-188	62	0.56	2.6	0.0	1.93	2.36
9	F-024	46	0.41	2.6	0.0	1.93	2.17
10	F-3922	67	0.54	2.8	0.0	1.92	2.21
11	F-3292	21	0.18	2.3	0.0	2.02	2.35
12	F-3231	15	0.13	2.3	0.0	1.95	2.27
13	G-0544	44	0.4	2.6	0.0	1.92	2.21
14	G-1045	56	0.48	1.5	0.0	1.93	2.17
15	G-0629	51	0.46	2.6	0.0	2.01	2.25
16	G-50	36	0.32	2.6	0.0	2.03	2.23
17	G-68	34	0.29	2.6	0.0	1.97	2.36
18	G-48	26	0.23	2.8	0.0	1.97	2.33

Table S1 Purified microRNA characteristics



Figure S1 Absolute quantitative HTS and bioinformatic analysis. (A) The experiment pipeline steps for sRNA-seq. (B) The bioinformatics pipeline. HTS, high-throughput sRNA sequencing; Primer Rev, primer reverse; Primer For, primer forward; DNB, DNA nanoball; miRNA, microRNA; siRNA, small interfering RNA; piRNA, PIWI-interacting RNA; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.



Figure S2 Schematic of stem-loop-based microRNA qRT-PCR. SLP, stem-loop primer; GSP, gene specific primer; URP, universal reverse primer.

Table S2 Primer set

Primers	Sequence
miR-34b-3p SLR	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGATGGCAGT
miR-34c-3p SLR	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCCTGGCCG
miR-3065-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCTCCAACA
miR-4446-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACCCATGT
miR-676-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAACTCAAC
miR-376a-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGACGTGGAT
miR-449b-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGAGTGGCAG
miR-202-5p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCAAAGAAG
miR-942-5p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCACATGGC
miR-518e-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCACTCTGA
miR-891b SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCAATGAC
miR-30b-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGGAAGTAAA
cel-miR-39-3p SLP	CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGCAAGCTGA
hsa-miR-34b-3p F	ACACTCCAGCTATACAATCACTAACT
hsa-miR-34c-3p F	ACACTCCAGCTATAAATCACTAACCA
hsa-miR-3065-3p F	ACACTCCAGCTATATCAGCACCAGG
hsa-miR-4446-3p F	ACACTCCAGCTATACAGGGCTGGC
hsa-miR-676-3p F	ACACTCCAGCTATACTGTCCTAAGGT
hsa-miR-376a-3p F	ACACTCCAGCTATAATCATAGAGGA
hsa-miR-449b-3p F	ACACTCCAGCTATACAGCCACAACTA
hsa-miR-202-5p F	ACACTCCAGCTATATTCCTATGCATA
hsa-miR-942-5p F	ACACTCCAGCTATATCTTCTCTGTTT
hsa-miR-518e-3p F	ACACTCCAGCTATAAAAGCGCTTCCC
hsa-miR-891b F	ACACTCCAGCTATATGCAACTTACCT
hsa-miR-30b-3p F	ACACTCCAGCTATACTGGGAGGTGGA
cel-miR-39-3p F	ACACTCCAGCTATATCACCGGGTGTA
mir-URP	CTCAACTGGTGTCGTGGAGTC
probe-34c	5'FAM/CAGTTGAGCCTGGCCGTG/3'MGB
probe-34b	5'HEX/CAGTTGAGA/T-BHQ/GGCAGTGGAGT/3'MGB
probe-3065	5'HEX/CAGTTGAGC/T-BHQ/CCAACAATATCCTGG/3'MGB
probe-4446	5'FAM/CAGTTGAGACCCA/T-BHQ/GTCACTGCCA/3'MGB
probe-cel-39	5'FAM/CAGTTGAGCAAGCTGATTTAC/3'MGB





© Annals of Translational Medicine. All rights reserved.

Micro-TESE outcome	*	Histopathologic	al diagnostic result	
(case number)	Sertoli-cell-only syndrome	Maturation arrest	Hypo-spermatogenesis	Normal
Good (n=18)	0	0	6	12
Fair (n=47)	3	38	6	0
Poor (n=57)	40	17	0	0

Table S3 Micro-TESE outcomes of NOA patients with different histological diagnosis



Figure S4 Histological diagnosis and micro-TESE outcome of enrolled patients. (A) HE staining of Sertoli-cell-only Syndrome (40fold magnification). (B) HE staining of Maturation Arrest (20-fold magnification). (C) HE staining of hypospermatogenesis (20-fold magnification). (D) An isolated region of micro-TESE from the "Fair" group, and the histopathological diagnosis was "Sertoli-cell-only" Syndrome (25-fold magnification). The region in the black box shows tubules with normal spermatogenesis. The adjacent testicular tissue contains tubules with no spermatogenesis pointed by black arrows. (E) An isolated region of micro-TESE from the "Good" group, and the histopathological diagnosis was "Maturation Arrest" (25-fold magnification). The region in the black box shows tubules with normal spermatogenesis.